The 12 mg weekly dose problem: when 30 mg vials get awkward A patient titrated to the upper Phase 2 retatrutide dose (12 mg weekly) and using a 30 mg vial faces a constraint: the dose volume needs to stay inside one U-100 syringe
NAD+ raised higher NAD+ feeds mitochondrial energy production and switches on sirtuin enzymes
Whether you are already using tirzepatide and considering adding AOD 9604, or you are researching this stack from scratch, this guide covers the mechanisms, the protocols, the safety data, and the practical details that most resources skip entirely
Common side effects are usually mild and temporary
This blend is ideal for individuals with complex injuries requiring multi-system support, athletes seeking comprehensive recovery, post-surgical patients needing accelerated healing, those with chronic inflammatory conditions, individuals dealing with gut health issues alongside tissue injuries, and anyone requiring simultaneous tissue repair, inflammation control, immune support, and cellular regeneration